%0 Journal Article
%T Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles.
%A Popoola DO
%A Cao Z
%A Men Y
%A Li X
%A Viapiano M
%A Wilkens S
%A Luo J
%A Teng Y
%A Meng Q
%A Li Y
%J Nano Lett
%V 24
%N 26
%D 2024 Jul 3
%M 38888232
%F 12.262
%R 10.1021/acs.nanolett.4c01854
%X Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA/LNP therapeutics mainly address liver diseases, the potential of mRNA therapy extends far beyond─yet to be unraveled. To fully unlock the promises of mRNA therapy, there is an urgent need to develop safe and effective LNP systems that can target extrahepatic organs. Here, we report on the development of sulfonium lipid nanoparticles (sLNPs) for systemic mRNA delivery to the lungs. sLNP effectively and specifically delivered mRNA to the lungs following intravenous administration in mice. No evidence of lung and systemic inflammation or toxicity in major organs was induced by sLNP. Our findings demonstrated that the newly developed lung-specific sLNP platform is both safe and efficacious. It holds great promise for advancing the development of new mRNA-based therapies for the treatment of lung-associated diseases and conditions.